3Yasuda Y, Kaleta J, Br? rome D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev, 2005,57 : 973-993.
4Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: insights into athogenesis, diagnostic challenges, and therapeutic options. Am J Med, 2008,121 : 748-757.
5Chiu HC, Kovacs A, Blanton RM,et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res, 2005,96:225-233.
6Liedtke AJ, DeMaison L, Eggleston AM,et al. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res, 1988,62 : 535-5842.
7Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension, 2005,45 : 828-833.
8Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE,2005,pe4.
9Gual P, Le Marehand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie, 2005,87:99-109.
10Baroueh LA, Berkowitz DE, Harrison RW,et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation, 2003,108: 754-759.
